JP2010535015A - 免疫原性のポリペプチドおよびモノクローナル抗体 - Google Patents

免疫原性のポリペプチドおよびモノクローナル抗体 Download PDF

Info

Publication number
JP2010535015A
JP2010535015A JP2010517242A JP2010517242A JP2010535015A JP 2010535015 A JP2010535015 A JP 2010535015A JP 2010517242 A JP2010517242 A JP 2010517242A JP 2010517242 A JP2010517242 A JP 2010517242A JP 2010535015 A JP2010535015 A JP 2010535015A
Authority
JP
Japan
Prior art keywords
seq
produced
hybridoma
nucleic acid
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010517242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535015A5 (https=
Inventor
オクス，マルティナ
ブルックス，ロジャー
チャールボイス，ロバート
イェソン，ジェレミー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of JP2010535015A publication Critical patent/JP2010535015A/ja
Publication of JP2010535015A5 publication Critical patent/JP2010535015A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
JP2010517242A 2007-07-23 2008-07-23 免疫原性のポリペプチドおよびモノクローナル抗体 Pending JP2010535015A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96172307P 2007-07-23 2007-07-23
PCT/CA2008/001353 WO2009012588A1 (en) 2007-07-23 2008-07-23 Immunogenic polypeptides and monoclonal antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013089148A Division JP6204053B2 (ja) 2007-07-23 2013-04-22 免疫原性のポリペプチドおよびモノクローナル抗体

Publications (2)

Publication Number Publication Date
JP2010535015A true JP2010535015A (ja) 2010-11-18
JP2010535015A5 JP2010535015A5 (https=) 2011-08-11

Family

ID=40280955

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010517242A Pending JP2010535015A (ja) 2007-07-23 2008-07-23 免疫原性のポリペプチドおよびモノクローナル抗体
JP2013089148A Expired - Fee Related JP6204053B2 (ja) 2007-07-23 2013-04-22 免疫原性のポリペプチドおよびモノクローナル抗体
JP2015196681A Pending JP2016005482A (ja) 2007-07-23 2015-10-02 免疫原性のポリペプチドおよびモノクローナル抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013089148A Expired - Fee Related JP6204053B2 (ja) 2007-07-23 2013-04-22 免疫原性のポリペプチドおよびモノクローナル抗体
JP2015196681A Pending JP2016005482A (ja) 2007-07-23 2015-10-02 免疫原性のポリペプチドおよびモノクローナル抗体

Country Status (12)

Country Link
US (1) US8337846B2 (https=)
EP (1) EP2183366B1 (https=)
JP (3) JP2010535015A (https=)
KR (1) KR101595234B1 (https=)
CN (1) CN101802198B (https=)
AU (1) AU2008280799B2 (https=)
BR (1) BRPI0814127A2 (https=)
CA (1) CA2694466A1 (https=)
ES (1) ES2397488T3 (https=)
IL (1) IL203429A0 (https=)
WO (1) WO2009012588A1 (https=)
ZA (1) ZA201001260B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021518559A (ja) * 2018-03-20 2021-08-02 サノフィ パスツ−ル リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 固有蛍光を使用して、アジュバント化タンパク質濃度及びパーセント吸着を決定する方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
CN102802664B (zh) 2009-12-22 2017-04-05 赛诺菲巴斯德有限公司 免疫原性组合物
US9649372B2 (en) 2009-12-22 2017-05-16 Sanofi Pasteur Limited Immunogenic compositions and related methods
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
KR20140009281A (ko) 2010-12-03 2014-01-22 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 스트렙토코커스 뉴모니애에 대한 면역화를 위한 조성물
WO2012156391A1 (en) 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
US9279815B2 (en) 2012-02-01 2016-03-08 Oklahoma Medical Research Foundation Human Streptococcus pneumoniae antibodies and uses therefor
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CN105754952B (zh) * 2016-02-16 2020-07-10 中国农业科学院兰州兽医研究所 抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
EP4291306A1 (en) * 2021-02-09 2023-12-20 University of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003054007A2 (en) * 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81370A (en) * 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
DE69233012T2 (de) * 1991-11-22 2003-11-06 Fattom, Ali Ibrahim Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
US6582708B1 (en) * 2000-06-28 2003-06-24 The Procter & Gamble Company Tooth whitening substance
ES2322306T3 (es) 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
ES2400280T3 (es) * 1998-12-23 2013-04-08 Id Biomedical Corporation Of Quebec Antígenos de estreptococos
US7128918B1 (en) * 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
CN100379758C (zh) * 1999-03-26 2008-04-09 科特克斯(Om)有限公司 肺炎链球菌抗原
AU2001269833A1 (en) * 2000-06-14 2001-12-24 Cytovax Biotechnologies, Inc. Use of coiled-coil structural scaffold to generate structure-specific peptides
US7074415B2 (en) * 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
AU2001270381B2 (en) * 2000-06-20 2007-05-24 Id Biomedical Corporation Streptococcus antigens
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
US6720918B2 (en) * 2002-09-17 2004-04-13 Space Systems/Loral, Inc. Antenna distortion estimation and compensation
EP2333114A1 (en) * 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
KR20060034698A (ko) * 2003-07-10 2006-04-24 와이어쓰 홀딩스 코포레이션 화농성 연쇄상구균 시스테인 프로테아제의 재조합 발현 및이의 면역원성 조성물
US8105612B2 (en) * 2005-05-13 2012-01-31 Novartis Vaccines And Diagnostics, Inc. Serum resistance factors of gram positive bacteria
JP5509176B2 (ja) * 2011-10-21 2014-06-04 株式会社日立製作所 計算機システムおよび計算機システムにおけるモジュール引き継ぎ方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003054007A2 (en) * 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021518559A (ja) * 2018-03-20 2021-08-02 サノフィ パスツ−ル リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 固有蛍光を使用して、アジュバント化タンパク質濃度及びパーセント吸着を決定する方法
JP7413271B2 (ja) 2018-03-20 2024-01-15 サノフィ パスツ－ル リミテッド 固有蛍光を使用して、アジュバント化タンパク質濃度及びパーセント吸着を決定する方法

Also Published As

Publication number Publication date
US8337846B2 (en) 2012-12-25
AU2008280799B2 (en) 2013-07-11
KR101595234B1 (ko) 2016-02-26
JP2013212108A (ja) 2013-10-17
IL203429A0 (en) 2011-07-31
ES2397488T3 (es) 2013-03-07
CN101802198B (zh) 2016-02-17
WO2009012588A1 (en) 2009-01-29
JP6204053B2 (ja) 2017-09-27
EP2183366B1 (en) 2012-10-24
CA2694466A1 (en) 2009-01-29
KR20100053564A (ko) 2010-05-20
JP2016005482A (ja) 2016-01-14
BRPI0814127A2 (pt) 2015-02-03
EP2183366A4 (en) 2010-09-01
US20100297133A1 (en) 2010-11-25
EP2183366A1 (en) 2010-05-12
AU2008280799A1 (en) 2009-01-29
ZA201001260B (en) 2010-10-27
CN101802198A (zh) 2010-08-11

Similar Documents

Publication Publication Date Title
JP6204053B2 (ja) 免疫原性のポリペプチドおよびモノクローナル抗体
KR101741426B1 (ko) 변형된 스트렙토코커스 뉴모니아 뉴몰리신(ｐｌｙ) 폴리펩타이드
CA2884918C (en) Salmonid alphavirus and uses thereof
KR20070122458A (ko) 표재성 스트렙토코커스 뉴모니아 폴리펩티드
AU2013204613A1 (en) Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
US20240100149A1 (en) Sars-cov-2 constructs, vaccines, and methods
US20160228500A9 (en) Immunogenic Polypeptides and Monoclonal Antibodies
Class et al. Patent application title: Immunogenic Polypeptides and Monoclonal Antibodies Inventors: Martina Ochs (Toronto, CA) Roger Brooks (Toronto, CA) Robert Charlebois (Toronto, CA) Jeremy Yethon (Milton, CA)
AU2016254447A1 (en) Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
HK1243089A1 (en) Immunogenic pcpa polypeptides and uses thereof
CA2634911A1 (en) Neisseria meningitidis vaccines and their use
CZ20004395A3 (cs) Antigenní polypeptidy Neisseria meningitidis, příslušné polynukleotidy a protektivní protilátky

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130618